AccurEdit Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Phase One Trial of ART001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Polyneuropathy

AccurEdit's ART001 becomes the first product to demonstrate safe and effective systemic CRISPR gene editing in humans in China

ART001 is well tolerated by all patients treated and demonstrates an outstanding safety profile. No >Grade 1 liver enzyme elevation was observed in any of the patients treated. So far, no patient in the study experienced infusion-related reaction, which was observed in 38% of the patients treated with a similar product previously.

AccurEdit and N1 Life Form a Joint Venture Named ‘Napoltec’

AccurEdit Therapeutics (Suzhou) Co., Ltd. ("AccurEdit"), an emerging company based on new generations of safe...

AccurEdit Raises Tens of Millions of Dollars in Seed Funding

AccurEdit Therapeutics (Suzhou) Co., Ltd. ("AccurEdit ") announced today that it had raised tens of millions of dollars in seed funding. The funding round was led by Legend Capital, a world-renowned medical investment institution, with participation from Cormorant. The raised fund will be used to support the construction of the R&D platform and the fast promotion of the company's pipelines.